Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Charles River Laboratories International's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3,597 Mil. Charles River Laboratories International's Total Assets for the quarter that ended in Dec. 2023 was $8,195 Mil.
Therefore, Charles River Laboratories International's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.44.
The historical rank and industry rank for Charles River Laboratories International's Equity-to-Asset or its related term are showing as below:
CRL'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.31 Med: 0.36 Max: 0.44
Current: 0.44
During the past 13 years, the highest Equity to Asset Ratio of Charles River Laboratories International was 0.44. The lowest was 0.31. And the median was 0.36.
CRL's Equity-to-Asset is ranked worse than 69.04% of 239
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.58
vs CRL: 0.44
Charles River Laboratories International Equity-to-Asset Historical Data
The historical data trend for Charles River Laboratories International's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Charles River Laboratories International Annual Data
For the Diagnostics & Research subindustry, Charles River Laboratories International's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International Equity-to-Asset Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's Equity-to-Asset falls into.
Charles River Laboratories International Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Charles River Laboratories International's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International (NYSE:CRL) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Charles River Laboratories International Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Charles River Laboratories International's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles River Laboratories International (Charles River Laboratories International) Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRL has been successfully added to your 